secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001140361-23-051485
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GNI Group, controlling shareholder of Gyre Therapeutics, raises FY2023 forecast; revenue +3.9%, op profit +21.5%
--------------------------------------------------------------------------------

- FY2023 revenue forecast raised to ¥26,267M (from ¥25,273M); operating profit to ¥7,280M (from ¥5,991M).
- Net profit attributable to parent raised to ¥2,005M; basic EPS revised to ¥42.20 from ¥35.86.
- ETUARY® sales in China exceeded expectations; Cullgen's Astellas alliance revenue above prior forecast.
- Forex assumptions revised: US$1=¥138.24 and RMB1=¥19.62 (from ¥130.77 and ¥19.38).
- Previous 2022 actuals: revenue ¥17,418M, net profit ¥388M, EPS ¥8.19.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123051485/0001140361-23-051485-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036123051485/ny20009756x14_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-051485

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer